10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Penile cancer is a squamous skin-type cancer for which HPV is the main risk factor. Caught early it is usually cured, with organ-sparing surgery where feasible, and HPV vaccination and circumcision help prevent it. The hard cases are those with lymph-node spread, where the InPACT trial is testing chemotherapy or chemoradiotherapy before surgery; it has closed to recruitment and has not reported.
Penile squamous cell carcinoma arises on the glans or foreskin and follows two pathways: HPV-related (HPV16 predominant, p16-positive, basaloid or warty histology) and HPV-independent (differentiated PeIN linked to lichen sclerosus and chronic inflammation, TP53 and CDKN2A alterations). The disease spreads predictably to inguinal then pelvic nodes, and nodal stage is the dominant prognostic factor. Management has shifted from amputation to organ-sparing surgery for most primary tumours (glansectomy, glans resurfacing, laser, Mohs, or brachytherapy), which preserves function without compromising cure when margins are clear.
The inguinal nodes decide outcome. Dynamic sentinel node biopsy stages clinically node-negative patients with high-risk primaries (stage pT1b or above in the 2023 guideline), sparing most of them a morbid lymphadenectomy; palpable or proven nodal disease is treated with radical inguinal (and, when indicated, pelvic) lymphadenectomy, with adjuvant chemotherapy or chemoradiation for extensive nodal disease. Cisplatin-based combinations (TIP: paclitaxel, ifosfamide, cisplatin) are the standard neoadjuvant and first-line regimens; the international InPACT trial (NCT02305654) is a randomised phase 3 study of the sequence of surgery, chemotherapy and radiotherapy in node-positive disease; the registry lists it as closed to recruitment, with primary completion estimated for May 2027 and no results posted. Immune checkpoint inhibitors (pembrolizumab, cemiplimab) have produced responses in small series. In the single-arm phase 2 HERCULES trial in Brazil (JAMA Oncology 2025), pembrolizumab with platinum and fluorouracil chemotherapy as first treatment for advanced disease gave a response in 39.4% of 33 evaluable men, with median overall survival of 9.6 months and no comparison arm. HPV-directed vaccines and cell therapies are being explored.
| Setting | Approach | Guideline |
|---|---|---|
| Primary tumour | Organ-sparing treatment where feasible (glansectomy, glans resurfacing, wide local excision, laser or brachytherapy); partial or total penectomy reserved for extensive tumours. | not mapped |
| Clinically node-negative, high-risk primary (pT1b or above) | Dynamic sentinel node biopsy (or modified inguinal lymphadenectomy where unavailable), which the EAU-ASCO 2023 guideline recommends for tumours of stage pT1b or above; its advice for lower-risk tumours could not be re-read in full on 18 November 2026. | not mapped |
| Node-positive | Radical inguinal lymphadenectomy; pelvic lymphadenectomy and adjuvant chemotherapy or chemoradiation for extensive disease; neoadjuvant TIP for bulky or fixed nodes (InPACT is testing the sequence). | NCCN Category 2A |
| Metastatic or recurrent | Cisplatin-based chemotherapy (TIP); checkpoint inhibitors in trials or where approved for tumour-agnostic indications; palliative radiotherapy. | not mapped |